Anti-Human GD2 (Naxitamab)

IVMB0413

Product Information

Product SKU :	IVMB0413	Clone:	hu3F8	Target:	GD2
Size:	100 mg, 50 mg, 25 mg, 5 mg, 1 mg			Isotype :	Human IgG1ĸ
Additional In	formation				
Additional In Reactivity:	formation Human			Host Species:	Human
	Human	oinant Human	Monoclonal Antibody	•	Human ost : HEK-293 Cells

Immunogen Information

Background:Neuroblastoma is an extracranial childhood cancer that accounts for 12% of cancer deaths
in children ¹. Neuroblastomas highly express the antigen GD2, a glycolipid that assists in the
attachment of tumor cells to the extracellular matrix ².

Naxitamab (hu3F8) is a humanized IgG1 anti-GD2 monoclonal antibody developed for the treatment of neuroblastoma, osteosarcoma, and other GD2-positive cancers ³. Naxitamab was engineered by grafting the complementarity determining regions of murine 3F8 (m3F8) onto human IgG1 frameworks and optimizing the sequences for stability, binding kinetics to GD2, and efficiency in antibody dependent cell-mediated cytotoxicity (ADCC) ⁴. Naxitamab demonstrates direct cytotoxicity against neuroblastoma cell line LAN-1 in vitro and induces complement dependent cytotoxicity as well as ADCC ³,⁴. Naxitamab has low level cross-reactivity with the ganglioside GD1b and no cross-reactivity with human N-CAM ⁴.

The chemical name for naxitamab is immunoglobulin G1, anti-(ganglioside GD2)
(humanized mus musculus clone hu3f8 gamma1-chain), disulfide with humanized mus
musculus clone hu3f8 light-chain, dimer ³.Endotoxin Level:< 1.0 EU/mg as determined by the LAL method</td>

Applications: in vivo





Synonyms:

human ganglioside GD2, disialoganglioside

 Antigen Distribution:
 GD2 is a cell surface glycolipid present in low concentrations on skin, neural, or peripheral nerve cell surfaces. GD2 is overexpressed on neuroblastoma cells, most melanoma, and some other tumors.

Immunogen: Human GD2

Formulation:This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate
buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium
or preservatives added. Due to inherent biochemical properties of antibodies, certain
products may be prone to precipitation over time. Precipitation may be removed by aseptic
centrifugation and/or filtration.

Specificity:This non-therapeutic biosimilar antibody uses the same variable region sequence as the
therapeutic antibody Naxitimab. Clone hu3F8 recognizes Human GD2. This product is for
research use only.

Recommended Isotype Human IgG1

Controls:

Storage & Handling:Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to
one month. For longer term storage, aseptically aliquot in working volumes without diluting
and store at -80°C. Avoid Repeated Freeze Thaw Cycles.